COVID-19：与Takeda和NovaVAX合作：每年生产2.5亿支疫苗
COVID-19：
武田：
我们已经与“ NovaVAX”达成了一项基本协议，并获得了为新的冠状病毒生产疫苗的技术。
山口县光市工厂：
武田在山口县光市的工厂准备生产设施。
另外，厚生劳动省也提供了301亿日元的赠款。
该公司计划为日本开发，生产和分销疫苗。
确保生产能力：
该公司每年的生产能力超过2.5亿支疫苗。
他希望能够在明年下半年生产出第一支疫苗，并获得国家批准。
这是武田首次与一家公司合作开发新的冠状病毒疫苗。
NHK新闻
Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan
Takeda now has a vaccine project in its fight against the COVID-19 pandemic, alongside repurposing existing drugs and developing a plasma-based therapy to treat the deadly disease.
The Japanese pharma
reached a deal with Novavax to develop, manufacture and sell the U.S. biotech’s coronavirus vaccine candidate, NVX-CoV2373, in Japan.
While the exact monetary terms were not disclosed, the pair said Japan’s health authorities will help fund technology transfer, new infrastructure and scale-up of manufacturing. The goal is to build up capacity to produce 250 million doses of the shot a year.
“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373,” Novavax CEO Stanley Erck said in a statement.
RELATED: Novavax’s COVID-19 vaccine looks promising in early data
Data from the phase 1 portion of a phase 1/2 study
showed two consecutive doses of the recombinant shot triggered neutralizing antibodies at levels numerically higher than those seen in patients who had recovered from COVID-19.
A month ago, the Maryland biotech snared a $1.6 billion financial commitment from the U.S. government’s Operation Warp Speed to support the vaccine’s late-stage testing and manufacturing.
In return, the company pledged to deliver 100 million doses beginning as early as late 2020, with potentially more to come.
FiercePharma
https://www.fiercepharma.com/vaccines/novavax-takeda-team-up-to-introduce-covid-19-vaccine-to-japan